Study of Selinexor with Carfilzomib, Isatuximab, and Dexamethasone for Patients with Relapsed or Hard-to-Treat Multiple Myeloma

Inclusion Criteria

• Must be 18 years or older.
• Have a diagnosis of relapsed or hard-to-treat multiple myeloma and have received at least one previous treatment.
• Have certain high-risk features in the cancer cells, such as specific genetic changes.
• Have measurable disease, meaning the cancer can be measured by tests or scans.
• Have good overall health with a performance status of 2 or less, unless bone pain is causing the higher score.
• Have adequate organ function based on blood tests.
• Women of childbearing potential must have a negative pregnancy test and agree to use contraception.
• Men must agree to use contraception and not donate sperm during the study.
• Be willing to provide blood and bone marrow samples for research.
• Patients with controlled HIV or hepatitis B/C infections may participate if the viral load is undetectable.
• Must be able to understand and agree to the study procedures.

Exclusion Criteria

• Have an active infection requiring treatment.
• Be pregnant or breastfeeding.
• Have another active cancer needing treatment, except for certain skin or cervical cancers.
• Have cancer that has spread to the brain unless treated and stable.
• Have had a severe allergic reaction to anti-CD38 antibodies.
• Have uncontrolled health issues like heart failure or unstable heart conditions.
• Have taken an investigational drug within 14 days before starting the study.
• Have digestive issues that prevent taking oral medication.
• Be taking certain medications that affect how the study drugs work and cannot stop them.
• Have had previous treatment with Selinexor or similar drugs.
• Have had anti-CD38 therapy within 6 months before the study.
• Have a heart function test showing less than 40% function.
• Have plasma cell leukemia or certain other blood disorders.